October 23, 2020

Early Use of Nitazoxanide in Mild Covid-19 Disease Randomized Placebo-Controlled Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] A multicenter, randomized, placebo-controlled trial of the antiparasitic drug nitazoxanide indicated that for patients with mild COVID-19, at 1-week follow-up, 78% of patients (n=194) who had received nitazoxanide and 57% who had received placebo (n=198) reported complete resolution of symptoms (p=0.048). Swabs collected were negative for SARS-CoV-2 in 30% of patients in the nitazoxanide group versus 18% in the placebo group (p=0.009), and viral load was significantly reduced after nitazoxanide compared to placebo (p=0.006). No deaths or life-threatening adverse events occurred in the nitazoxanide group.

Rocco et al. (Oct 23, 2020). Early Use of Nitazoxanide in Mild Covid-19 Disease Randomized Placebo-Controlled Trial. Pre-print downloaded Oct 23 from https://doi.org/10.1101/2020.10.21.20217208